User profiles for Lianne Siegel
 | Lianne SiegelAssistant Professor, Division of Biostatistics, University of Minnesota Verified email at umn.edu Cited by 625 |
[HTML][HTML] Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …
…, M Pullen, EL Wirtz, LK Siegel… - The Lancet Infectious …, 2023 - thelancet.com
Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
[HTML][HTML] The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
Background Studies included in a meta-analysis are often heterogeneous. The traditional
random-effects models assume their true effects to follow a normal distribution, while it is …
random-effects models assume their true effects to follow a normal distribution, while it is …
[HTML][HTML] Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
…, C Tignanelli, J Thompson, M Pullen, L Siegel… - medRxiv, 2022 - ncbi.nlm.nih.gov
Background Long Covid is an emerging chronic illness potentially affecting millions, sometimes
preventing the ability to work or participate in normal daily activities. COVID-OUT was an …
preventing the ability to work or participate in normal daily activities. COVID-OUT was an …
[HTML][HTML] Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles
Purpose Heterogeneity has been observed in outcomes of hospitalized patients with
coronavirus disease 2019 (COVID-19). Identification of clinical phenotypes may facilitate tailored …
coronavirus disease 2019 (COVID-19). Identification of clinical phenotypes may facilitate tailored …
[HTML][HTML] RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19
KD Wick, L Siegel, JD Neaton, C Oldmixon… - JCI insight, 2022 - ncbi.nlm.nih.gov
Background The value of the soluble receptor for advanced glycation end-products (sRAGE)
as a biomarker in COVID-19 is not well understood. We tested the association between …
as a biomarker in COVID-19 is not well understood. We tested the association between …
Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas
A Toyama, L Siegel, AC Nelson, M Najmuddin, L Bu… - Modern …, 2019 - nature.com
Mucosal melanomas are rare, and less is known about the biomarkers of this subtype in
comparison to cutaneous or uveal melanomas. Preferentially expressed antigen in melanoma (…
comparison to cutaneous or uveal melanomas. Preferentially expressed antigen in melanoma (…
[HTML][HTML] Metformin reduces sars-cov-2 in a phase 3 randomized placebo controlled clinical trial
…, K Cohen, MA Puskarich, HK Belani, LK Siegel… - medRxiv, 2023 - ncbi.nlm.nih.gov
Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot
be used with many medications, and are limited to virus-specific targets. 1–3 Biophysical …
be used with many medications, and are limited to virus-specific targets. 1–3 Biophysical …
Vaccination against SARS-CoV-2 is associated with a lower viral load and likelihood of systemic symptoms
…, N Ingraham, G Christensen, L Siegel… - Open forum …, 2022 - academic.oup.com
Background Data conflict on whether vaccination decreases severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare …
coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare …
Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of …
…, MA Puskarich, HK Belani, LK Siegel… - Clinical Infectious …, 2024 - academic.oup.com
Background Metformin has antiviral activity against RNA viruses including severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression …
respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression …
